The clinical use of molecular targeted therapy is rapidly evolving but has primarily focused
on genomic alterations. Transcriptomic analysis offers an opportunity to dissect the …

Cancer Biomarkers are the key to unlocking the promise of precision oncology, selecting
which patients will respond to a more personalised treatment while sparing non-responders …

Biomarkers that predict likely response or resistance to specific therapies are critical in
personalising treatment for cancer patients. Such biomarkers are now available for an …

Following treatment with androgen receptor (AR) pathway inhibitors,≈ 20% of prostate
cancer patients progress by shedding their AR‐dependence. These tumors undergo …

Expression of the DNA/RNA helicase schlafen family member 11 (SLFN11) has been
identified as a sensitizer of tumor cells to DNA-damaging agents including platinum …

Background Targeted sequencing of circulating tumour DNA (ctDNA) is a promising tool to
monitor dynamic changes in the variant allele frequencies (VAF) of genomic alterations and …

Intracranial metastases in prostate cancer are uncommon but clinically aggressive. A
detailed molecular characterization of prostate cancer intracranial metastases would …

Background Genomic alterations play important roles in the development of cancer. We
explored the impact of protein-coding genes and transcriptomic changes on clinical and …

Background Altered tumor suppressor genes (TSG-alt) in prostate cancer are associated
with worse outcomes. The prognostic value of TSG-alt in metastatic, hormone-sensitive …

The prevalence and biological consequences of deleterious germline variants in urothelial
cancer (UC) are not fully characterized. We performed whole-exome sequencing (WES) of …